You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
先為達計劃將減肥針埃諾格魯(月太)注射液引入美國
阿思達克 07-25 16:05
杭州先為達生物科技公司董事長潘海向《路透》表示,公司正在與一間美國公司進行談判,有意向美國患者引入實驗性減肥藥物埃諾格魯(月太)注射液。 數據顯示,使用埃諾格魯(月太)注射液的超重患者平均體重減輕10%至15%,與Novo Nordisk的最暢銷的減重藥Wegovy的結果大致一致。 潘海未有透露潛在的合作美國公司以及相關的財務條款,但稱潛在合作夥伴希望獲得美國上市許可,將埃諾格魯(月太)注射液用於多種疾病,並將進行進一步的臨床測試,合作夥伴預計至少需要三年時間才能將埃諾格魯(月太)注射液推向美國市場。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account